Extended-Spectrum β-Lactamases in Klebsiella pneumoniae Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTX-M-Type β-Lactamases

ABSTRACT A huge variety of extended-spectrum β-lactamases (ESBLs) have been detected during the last 20 years. The majority of these have been of the TEM or SHV lineage. We have assessed ESBLs occurring among a collection of 455 bloodstream isolates of Klebsiella pneumoniae, collected from 12 hospitals in seven countries. Multiple β-lactamases were produced by isolates with phenotypic evidence of ESBL production (mean of 2.7 β-lactamases per isolate; range, 1 to 5). SHV-type ESBLs were the most common ESBL, occurring in 67.1% (49 of 73) of isolates with phenotypic evidence of ESBL production. In contrast, TEM-type ESBLs (TEM-10 type, -12 type, -26 type, and -63 type) were found in just 16.4% (12 of 73) of isolates. The finding of TEM-10 type and TEM-12 type represents the first detection of a TEM-type ESBL in South America. PER (for Pseudomonas extended resistance)-type β-lactamases were detected in five of the nine isolates from Turkey and were found with SHV-2-type and SHV-5-type ESBLs in two of the isolates. CTX-M-type ESBLs (blaCTX-M-2 type and blaCTX-M-3 type) were found in 23.3% (17 of 73) of isolates and were found in all study countries except for the United States. We also detected CTX-M-type ESBLs in four countries where they have previously not been described—Australia, Belgium, Turkey, and South Africa. The widespread emergence and proliferation of CTX-M-type ESBLs is particularly noteworthy and may have important implications for clinical microbiology laboratories and for physicians treating patients with serious K. pneumoniae infections.

[1]  J. Sutcliffe,et al.  Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[3]  R. Cluzel,et al.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase. , 1987, The Journal of antimicrobial chemotherapy.

[4]  Patrick Legrand,et al.  TRANSFERABLE ENZYMATIC RESISTANCE TO THIRD-GENERATION CEPHALOSPORINS DURING NOSOCOMIAL OUTBREAK OF MULTIRESISTANT KLEBSIELLA PNEUMONIAE , 1987, The Lancet.

[5]  A. Huletsky,et al.  Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type beta-lactamases probed by site-directed mutagenesis and three-dimensional modeling. , 1993, The Journal of biological chemistry.

[6]  D. Livermore,et al.  Resistance to extended-spectrum cephalosporins, caused by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, Turkey. , 1995, Journal of medical microbiology.

[7]  I. Stemplinger,et al.  Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase , 1996, Antimicrobial agents and chemotherapy.

[8]  I. Stemplinger,et al.  Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases , 1996, Antimicrobial agents and chemotherapy.

[9]  H. Leblebicioglu,et al.  Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study , 1997, Antimicrobial agents and chemotherapy.

[10]  G. Storch,et al.  CTX-M-5, a Novel Cefotaxime-Hydrolyzing β-Lactamase from an Outbreak of Salmonella typhimuriumin Latvia , 1998, Antimicrobial Agents and Chemotherapy.

[11]  P. Nordmann,et al.  Role of residues 104, 164, 166, 238 and 240 in the substrate profile of PER-1 beta-lactamase hydrolysing third-generation cephalosporins. , 1998, The Biochemical journal.

[12]  H. Leblebicioglu,et al.  Widespread Detection of PER-1-Type Extended-Spectrum β-Lactamases among NosocomialAcinetobacter and Pseudomonas aeruginosaIsolates in Turkey: a Nationwide Multicenter Study , 1998, Antimicrobial Agents and Chemotherapy.

[13]  M. Gazouli,et al.  Spread of a Salmonella typhimurium Clone Resistant to Expanded-Spectrum Cephalosporins in Three European Countries , 1999, Journal of Clinical Microbiology.

[14]  V. Jarlier,et al.  Site-directed mutagenesis of residues 164, 170, 171, 179, 220, 237 and 242 in PER-1 beta-lactamase hydrolysing expanded-spectrum cephalosporins. , 1999, Protein engineering.

[15]  G. Jacoby,et al.  Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[16]  G. Rossolini,et al.  PER-1 extended-spectrum beta-lactamase production in an Alcaligenes faecalis clinical isolate resistant to expanded-spectrum cephalosporins and monobactams from a hospital in Northern Italy. , 2000, Microbial drug resistance.

[17]  L. Tzouvelekis,et al.  CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymes , 2000 .

[18]  J. Samama,et al.  The high resolution crystal structure for class A beta-lactamase PER-1 reveals the bases for its increase in breadth of activity. , 2000, The Journal of biological chemistry.

[19]  F. Luzzaro,et al.  Extended-Spectrum TEM- and SHV-Type β-Lactamase-Producing Klebsiella pneumoniae Strains Causing Outbreaks in Intensive Care Units in Italy , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[20]  H. Goossens,et al.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Nicolas-Chanoine,et al.  Updated Sequence Information and Proposed Nomenclature for blaTEM Genes and Their Promoters , 2000, Antimicrobial Agents and Chemotherapy.

[22]  C. Segura,et al.  SHV-1 β-Lactamase Is Mainly a Chromosomally Encoded Species-Specific Enzyme in Klebsiella pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[23]  D. Livermore,et al.  Complexity and Diversity of Klebsiella pneumoniae Strains with Extended-Spectrum β-Lactamases Isolated in 1994 and 1996 at a Teaching Hospital in Durban, South Africa , 2001, Antimicrobial Agents and Chemotherapy.

[24]  L. Rice,et al.  Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[25]  X. Bertrand,et al.  Pseudomonas aeruginosa: antibiotic susceptibility and genotypic characterization of strains isolated in the intensive care unit. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  O. Tansel,et al.  Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. , 2001, Journal of medical microbiology.

[27]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[28]  W. Bilker,et al.  Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  R. Bonomo,et al.  Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. , 2001, Biochimica et biophysica acta.

[30]  R. Bonnet,et al.  Novel Cefotaximase (CTX-M-16) with Increased Catalytic Efficiency Due to Substitution Asp-240→Gly , 2001, Antimicrobial Agents and Chemotherapy.

[31]  P. Bradford.  Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[32]  Victor L. Yu,et al.  Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory , 2001, Journal of Clinical Microbiology.

[33]  Molecular Epidemiology of Extended-Spectrum β-Lactamases from Klebsiella pneumoniae Strains Isolated in Zagreb, Croatia , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[34]  P. Nordmann,et al.  Characterization of a Chromosomally Encoded Extended-Spectrum Class A β-Lactamase from Kluyvera cryocrescens , 2001, Antimicrobial Agents and Chemotherapy.

[35]  Jon E. Ness,et al.  Predicting the emergence of antibiotic resistance by directed evolution and structural analysis , 2001, Nature Structural Biology.

[36]  M. Page,et al.  Development of a Sensitive and Specific Enzyme-Linked Immunosorbent Assay for Detecting and Quantifying CMY-2 and SHV β-Lactamases , 2002, Journal of Clinical Microbiology.

[37]  P. Grimont,et al.  β-Lactamases of Kluyvera ascorbata, Probable Progenitors of Some Plasmid-Encoded CTX-M Types , 2002, Antimicrobial Agents and Chemotherapy.

[38]  Christopher B. Howard,et al.  Identification and Minisequencing-Based Discrimination of SHV β-Lactamases in Nosocomial Infection-Associated Klebsiella pneumoniae in Brisbane, Australia , 2002, Antimicrobial Agents and Chemotherapy.

[39]  A. Oliver,et al.  Genes Encoding TEM-4, SHV-2, and CTX-M-10 Extended-Spectrum β-Lactamases Are Carried by Multiple Klebsiella pneumoniae Clones in a Single Hospital (Madrid, 1989 to 2000) , 2002, Antimicrobial Agents and Chemotherapy.

[40]  E. S. Moland,et al.  Occurrence of Newer β-Lactamases in Klebsiella pneumoniae Isolates from 24 U.S. Hospitals , 2002, Antimicrobial Agents and Chemotherapy.

[41]  P. Bradford,et al.  Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  J. Heritage,et al.  Three Cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China , 2002, Antimicrobial Agents and Chemotherapy.

[43]  Ronald N. Jones,et al.  Cefepime MIC as a Predictor of the Extended-Spectrum β-Lactamase Type in Klebsiella pneumoniae, Taiwan , 2002, Emerging infectious diseases.

[44]  P. Nordmann,et al.  Chromosome-Encoded Ambler Class A β-Lactamase of Kluyvera georgiana, a Probable Progenitor of a Subgroup of CTX-M Extended-Spectrum β-Lactamases , 2002, Antimicrobial Agents and Chemotherapy.

[45]  Robert A Bonomo,et al.  Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. , 2003, Journal of molecular biology.

[46]  M. Caniça,et al.  A novel sequence framework (bla(TEM-1G)) encoding the parental TEM-1 beta-lactamase. , 2003, FEMS microbiology letters.

[47]  S. Mitsuhashi,et al.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens , 1983, Infection.

[48]  A. Bauernfeind,et al.  A new plasmidic cefotaximase from patients infected withSalmonella typhimurium , 1992, Infection.